Last reviewed · How we verify

NCT04292405: ACAB

Accuracy of Cardiac Acoustic Biomarkers Recorded by the Wearable Cardioverter Defibrillator

Terminated Last updated 30 October 2025
What this trial tests

trial testing Wearable Cardioverter Defibrillator in Heart Failure in 60 participants. Terminated before completion.

Timeline
23 January 2020
Primary endpoint
30 September 2025
30 September 2025

Quick facts

Lead sponsorZoll Medical Corporation
StatusTerminated
Study typeOBSERVATIONAL
Enrollment60
Start date23 January 2020
Primary completion30 September 2025
Estimated completion30 September 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Zoll Medical Corporation — full company profile →

Who can join

18 and older, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluate data accuracy of cardiac acoustic biomarkers (CABs) recorded by the Wearable Cardioverter Defibrillator (WCD) as compared to the AUDICOR AM acoustic cardiography recorder.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Wearable Cardioverter Defibrillator

Trials testing the same drug.

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

Other Zoll Medical Corporation trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04292405.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing